On April 6, 2022 Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biopharmaceutical company, reported that it will present new Phase 2 US clinical study data regarding its lead drug candidate, EC-18 for chemoradiation-induced oral mucositis (CRIOM) at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2022 annual meeting, which will be held in-person on June 3-7th, 2022 in Chicago (Press release, Enzychem Lifesciences, APR 6, 2022, View Source [SID1234611525]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The abstract highlights the new clinical data from Enzychem’s Phase 2 US clinical trial evaluating the effect of EC-18 on severe oral mucositis (SOM) development in chemoradiation-treated head and neck cancer patients. Dr. Christina Henson, a board-certified Radiation Oncologist and Residency Program Director for Radiation Oncology at the University of Oklahoma will present the following abstract. She was also the highest enrolling site’s principal investigator of the Phase 2 study.
The details of the presentation are as follows:
Title: Phase 2, Randomized, Double-Blind Trial of EC-18 versus Placebo to Mitigate the Development and Time Course of Oral Mucositis from Concomitant Chemoradiation for Head and Neck Cancer
Presenter: Christina Henson, M.D
Date: June 4th, 2022
Time: 1:15-4:15 PM (CDT)